David Nierengarten

David Nierengarten

Analyst-Equity bij
Wedbush Securities, Inc.
Finance
Consumer Services
Health Technology

Profiel

Dr. David Nierengarten is a Senior Analyst at Wedbush Securities, Inc. Dr. David Nierengarten, Ph.D., has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy.
His prior experience in venture capital and operations at a private biotechnology company, helps him succeed in analyzing both science and business models.
In addition, Dr. David Nierengarten, Ph.D.
has results in predicting Dendreon's looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor.
Dr. David Nierengarten, Ph.D.
received his B.S.
in Biochemistry from the University of Wisconsin-Madison, and Ph.D.
in Molecular and Cell Biology from the University of California at Berkeley.

Actieve functies van David Nierengarten

BedrijvenFunctieBegin
Analyst-Equity -

Eerdere bekende functies van David Nierengarten

BedrijvenFunctieEinde
Corporate Officer/Principal 30-11-2010
Analyst-Equity 30-06-2007
Corporate Officer/Principal 30-05-2007
Corporate Officer/Principal 31-12-2004
Ervaring van David Nierengarten in detail bekijken

Opleiding van David Nierengarten

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

100 +

Eerstegraads connecties

7

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit7

Finance

Health Technology

Finance

Consumer Services

Consumer Services

Finance

Finance

  1. Beurs
  2. Insiders
  3. David Nierengarten